摘要
目的探讨苦参碱联合胸腺五肽对经腹腔热化疗治疗的卵巢癌大鼠免疫功能的影响。方法将46只成功造模的卵巢癌大鼠随机分为对照组和观察组,每组23只,两组大鼠均进行腹腔热化疗(顺铂)并同时给予胸腺五肽,观察组大鼠在此基础上给予苦参碱,共进行3周。比较两组大鼠治疗前后腹围、体重、免疫功能、血清CA125水平变化情况。结果治疗后,两组大鼠体重、腹围增加(P<0.05)观察组大鼠体重、腹围低于对照组(P<0.05)。治疗后,两组血清CD_3、CD_4、自然杀伤细胞(NK)、IgG、IgM、IgA浓度与CD_4/CD_8较治疗前降低(P<0.05),CD_8较治疗前升高(P<0.05);观察组患者血清CD_3、CD_4、CD_4/CD_8、IgG、IgM、IgA浓度明显高于对照组(P<0.05),CD_8较对照组降低(P<0.05)。治疗后,两组大鼠IL-2、IL-4浓度降低(P<0.05),且观察组IL-2、IL-4浓度明显高于对照组(P<0.05);两组IL-6、IL-12浓度较治疗前升高(P<0.05),且观察组IL-6、IL-12浓度明显低于对照组(P<0.05);两组大鼠CA125水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。结论对行腹腔热化疗的卵巢癌大鼠给予苦参碱联合胸腺五肽,有助于改善卵巢癌大鼠的免疫功能与一般状态。
Objective To study the effects of matrine combined with thymopeptide-5 on immune function of rats with ovarian carcinoma treated by intraperito neal hyperthermic chemotherapy.Methods Totally 46 rats which were successfully modelled asovarian carcinoma were randomly divided into two groups:observation group(n = 23)and control group(n = 23).All the rats were given intraperito neal hyperthermic chemotherapy(cis-platinum) and thy—mopeptide-5,and the rats in observation group were added with matrine,the course of treatment lasted for 3 weeks.The waist circumference,weight,index of immune function,and the level of CA125 in the two groups were compared before and after treatment.Results After treatment,the waist circumference and weight of rats increased(P〈0.05),and those in observation group were lower(P〈0.05).After treatment,the levels of CD3,CD4,NK,IgG,IgM,IgA,IL-2,IL-4,CD4/CD8 and CA125 decreased significantly(P〈0.05),while the levels of CD8,IL-12,and IL-6 increased(P〈0.05),and there were significant differences in the above indexes between the two groups(P〈0.05).Conclusion Matrine combined with thymopeptide-5 can improve the general state and the immune function in rats with ovarian carcinoma treated by intraperitoneal hyperthermic chemotherapy.
出处
《实用药物与临床》
CAS
2017年第1期4-8,共5页
Practical Pharmacy and Clinical Remedies
基金
辽宁省自然科学基金项目(2013225021)
关键词
卵巢癌
苦参碱
胸腺五肽
腹腔热化疗
免疫功能
CA125
Ovarian carcinoma
Matrine
Thymopeptide-5
Intraperitoneal hyperthermic chemotherapy
Immune function
CA125